{
    "clinical_study": {
        "@rank": "73893", 
        "arm_group": {
            "arm_group_label": "Selatinib Ditosilate Tablets", 
            "arm_group_type": "Experimental", 
            "description": "Selatinib Ditosilate either at 450,750,1000,1250mg, p.o. once daily"
        }, 
        "brief_summary": {
            "textblock": "Brief Description:\n\n      This study is designed to evaluate the safety and tolerability of oral Selatinib Ditosilate\n      Tablets, and explore the maximum tolerated dose (MTD) and dose-limiting toxicity in patients\n      with advanced breast cancer."
        }, 
        "brief_title": "A Phase Ib Study of Selatinib Ditosilate Tablets in Patients With Advanced Breast Cancer", 
        "condition": "Advanced Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "1. To evaluate the safety and tolerability of oral Selatinib Ditosilate Tablets, and\n           explore the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT).\n\n        2. To determine the pharmacokinetic profile of single and multi oral Selatinib Ditosilate\n           Tablets .\n\n        3. To determine preliminary dose and regimen for phase II study of oral Selatinib\n           Ditosilate Tablets.\n\n        4. To assess preliminary antitumor activity ."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  women aged 18-65.\n\n          -  Patients with ECOG performance status of 0 or 1.\n\n          -  Expected life-expectancy of more than 3 months.\n\n          -  Patients must have histologically or cytologically confirmed breast cancer. Either\n             the primary breast tumor or the metastasis must overexpress HER2;  acceptable methods\n             of measurement of HER2 expression include immunohistochemistry (IHC) and fluorescence\n             in situ hybridization (FISH); tumors tested by IHC must be 3+ positive for HER2\n             overexpression immunohistochemistry ; tumors tested by FISH must be positive.\n\n          -  Prior Herceptin therapy is discontinued because of disease progression or patients\n             can not afford for Herceptin therapy.\n\n          -  patients with at least one measurable lesion (RECIST1.1 criteria).\n\n          -  Hematology\uff1a WBC\u22653.5\u00d7109/L, ANC\u22651.5\u00d7109/L, PLT\u2265100\u00d7109/L\uff0cHB\u226590g/L;\n\n          -  Biochemistry\uff1a Serum bilirubin\u22641.5 times upper limit of normal (ULN),AST and ALT \u22641.5\n             times ULN;  creatinine and urea nitrogen\u22641.5 times ULN; LVEF\u226550%, ECG normal, and\n             Fridericia corrected QT(QTcF)\uff1c470ms.\n\n          -  patients receiving damage caused by other therapeutic has been restored, the interval\n             more than six weeks since the last receiving nitroso or mitomycin; more than 4 weeks\n             since last receiving radiotherapy, other cytotoxic drugs or surgery.\n\n          -  Subjects can swallow and have normal gastrointestinal function.\n\n          -  Female subjects should agree to take contraceptives during the study and within 6\n             months after the study (such as intrauterine device [IUD], contraceptive drugs or\n             condoms); within 7 days before they enter the study, their serum or human chorionic\n             gonadotropin should be negative, and must be in the non-lactation period.\n\n          -  Ability to understand and the willingness to sign a written informed consent\n             document.\n\n        Exclusion Criteria:\n\n          -  Patients have uncontrolled large pleural effusion and ascites.\n\n          -  Patients  have  received steroid for more than 50 days, or requiring for steroid\n             therapy for a long time.\n\n          -  Requirement for the therapeutic drugs prolonging  QT interval(such as anti-arrhythmia\n             drugs), and can not interrupt them.\n\n          -  Patients with a history of symptomatic brain metastases.\n\n          -  Patients have received small molecule  targeted drug  therapy of inhibition of  HER-2\n             or EGFR.\n\n          -  Patients have participated in other drug clinical research in the past 4 weeks.\n\n          -  Pregnant or lactating women are excluded from this study.\n\n          -  Patients with a history of  allergic reactions attributed to compounds of similar\n             chemical composition to the agents used in the study are ineligible;\n\n          -  Patients with active infection ;\n\n          -  Patients with cardiac disease  including Angina, any significant or need to be\n             treated arrhythmia\uff0cMyocardial infarction, Heart failure, LVEF<45%, other heart\n             diseases that are not suitable for participating in the study judged by investigator.\n\n          -  Patients with other concurrent severe and/or uncontrolled medical conditions\n             \uff08including hypertension, severe diabetes, thyroid disease, etc.) that could cause\n             unacceptable safety risks or compromise compliance with study requirements are\n             ineligible.\n\n          -  Patients with a history of mental disorders, including epilepsy or dementia are\n             ineligible."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01931943", 
            "org_study_id": "QLSLTN-102"
        }, 
        "intervention": {
            "arm_group_label": "Selatinib Ditosilate Tablets", 
            "intervention_name": "selatinib ditosilate tablets", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 27, 2013", 
        "location": {
            "contact": {
                "email": "cheryliqing@aliyun.com", 
                "last_name": "Qing Li"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100021"
                }, 
                "name": "Cancer Institute and Hospital,Chinese Academy of Medical Sciences"
            }, 
            "investigator": [
                {
                    "last_name": "Qing Li", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Binghe Xu", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase Ib Study to Evaluate the Tolerability and Pharmacokinetics of Selatinib Ditosilate Tablets in Patients With Advanced Breast Cancer", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Dose-limiting toxicity(DLT)", 
                "safety_issue": "Yes", 
                "time_frame": "21 days"
            }, 
            {
                "measure": "Maximum tolerated dose(MTD)", 
                "safety_issue": "Yes", 
                "time_frame": "21 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01931943"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Selatinib Ditosilate pharmacokinetic parameters , include AUC, Cmax, Tmax, and t1/2", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "21 days"
            }, 
            {
                "description": "The response of Salatinib Ditosilate on tumor measured by CT or MRI.", 
                "measure": "Pharmacodynamics", 
                "safety_issue": "No", 
                "time_frame": "7 weeks"
            }
        ], 
        "source": "Qilu Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Qilu Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}